Free Trial

Geron (GERN) Competitors

Geron logo
$1.40 +0.01 (+0.43%)
As of 09:30 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GERN vs. ALKS, LGND, BCRX, FOLD, CLDX, INVA, DVAX, MNKD, OPK, and NVAX

Should you be buying Geron stock or one of its competitors? The main competitors of Geron include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), and Novavax (NVAX). These companies are all part of the "biotechnology" industry.

Geron vs. Its Competitors

Alkermes (NASDAQ:ALKS) and Geron (NASDAQ:GERN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Alkermes has a net margin of 23.30% compared to Geron's net margin of -119.54%. Alkermes' return on equity of 27.52% beat Geron's return on equity.

Company Net Margins Return on Equity Return on Assets
Alkermes23.30% 27.52% 17.98%
Geron -119.54%-47.86%-26.78%

In the previous week, Alkermes had 8 more articles in the media than Geron. MarketBeat recorded 9 mentions for Alkermes and 1 mentions for Geron. Alkermes' average media sentiment score of 1.26 beat Geron's score of 0.00 indicating that Alkermes is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alkermes
4 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Geron
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkermes$1.56B3.15$367.07M$2.0914.23
Geron$76.99M11.55-$174.57M-$0.21-6.65

Alkermes currently has a consensus price target of $40.00, suggesting a potential upside of 34.54%. Geron has a consensus price target of $5.06, suggesting a potential upside of 262.64%. Given Geron's higher possible upside, analysts clearly believe Geron is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alkermes
0 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.83
Geron
0 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.78

Alkermes has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Comparatively, Geron has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 4.4% of Alkermes shares are owned by insiders. Comparatively, 7.4% of Geron shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Alkermes beats Geron on 12 of the 16 factors compared between the two stocks.

Get Geron News Delivered to You Automatically

Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GERN vs. The Competition

MetricGeronMED IndustryMedical SectorNASDAQ Exchange
Market Cap$889.14M$2.88B$5.50B$8.94B
Dividend YieldN/A2.45%5.25%4.04%
P/E Ratio-6.6520.8026.9720.11
Price / Sales11.55287.03426.02119.76
Price / CashN/A41.1936.8257.86
Price / Book3.037.487.985.56
Net Income-$174.57M-$55.04M$3.16B$248.40M
7 Day Performance-0.29%2.44%2.36%4.67%
1 Month Performance-13.83%1.90%2.15%6.64%
1 Year Performance-69.52%4.35%33.78%21.31%

Geron Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GERN
Geron
2.8462 of 5 stars
$1.40
+0.4%
$5.06
+262.6%
-69.3%$889.14M$76.99M-6.6570
ALKS
Alkermes
4.9324 of 5 stars
$28.60
-0.7%
$40.00
+39.9%
+20.6%$4.72B$1.56B13.681,800Positive News
LGND
Ligand Pharmaceuticals
4.7539 of 5 stars
$113.68
-0.4%
$146.14
+28.6%
+32.5%$2.19B$167.13M-15.9780
BCRX
BioCryst Pharmaceuticals
4.4608 of 5 stars
$8.96
-4.3%
$16.89
+88.5%
+36.9%$1.87B$450.71M-34.46530
FOLD
Amicus Therapeutics
3.6799 of 5 stars
$5.73
-3.4%
$16.22
+183.1%
-38.8%$1.76B$528.29M-63.66480
CLDX
Celldex Therapeutics
3.0711 of 5 stars
$20.35
+0.3%
$50.11
+146.2%
-41.3%$1.35B$7.02M-7.54150Positive News
INVA
Innoviva
3.8693 of 5 stars
$20.09
+0.7%
$55.00
+173.8%
+16.0%$1.26B$358.71M-19.89100
DVAX
Dynavax Technologies
4.3583 of 5 stars
$9.92
+0.1%
$24.00
+141.9%
-5.3%$1.19B$277.25M-19.08350
MNKD
MannKind
2.523 of 5 stars
$3.74
-0.5%
$10.33
+176.3%
-32.8%$1.14B$297.60M37.40400Negative News
OPK
OPKO Health
4.5376 of 5 stars
$1.32
flat
$2.75
+108.3%
+5.4%$1.05B$713.10M-18.852,997
NVAX
Novavax
4.488 of 5 stars
$6.30
-1.1%
$17.00
+169.8%
-41.6%$1.02B$682.16M2.381,990

Related Companies and Tools


This page (NASDAQ:GERN) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners